Literature DB >> 27690264

Measurement of fat content in vertebral marrow using a modified dixon sequence to differentiate benign from malignant processes.

Hye Jin Yoo1,2, Sung Hwan Hong1,2,3, Dong Hyun Kim1, Ja-Young Choi1,2, Hee Dong Chae1,2, Bo Mi Jeong1, Joong Mo Ahn2,4, Heung Sik Kang2,3,4.   

Abstract

PURPOSE: To determine whether fat-signal-fraction (FF) map using a modified Dixon sequence could help differentiate benign from malignant bone lesions.
MATERIALS AND METHODS: Spine magnetic resonance images (MRIs) of 120 consecutive patients were studied by using a 3T MRI with standard T1 -weighted image (T1 WI) and modified-Dixon sequence for FF measurement. There were three groups: a control group (n = 51) with normal vertebrae; a benign group (n = 40) with focal red marrow deposition, Schmorl's nodes, benign compression fracture, or Modic type 1 endplate degeneration; a malignant group (n = 29) with spinal malignancies. The following three parameters were measured on T1 WI and FF map by two radiologists independently: T1 signal intensity (SI), FF and T1 SI of normal disc (SI). Then, Lesion-to-disc ratio (LDR = SI of the lesion/SId ) and FF ratio of lesion and normal marrow were calculated. The mean values of the parameters were compared among the groups and Receiver Operating Characteristic (ROC) curves were analyzed. Then a logistic regression was performed.
RESULTS: The FF (2.8%) and FF ratio (0.082) of malignancy were lower than benign lesions (P < 0.001). There was no difference in the LDR between malignancy and Schmorl's nodes (P = 0.795) or a benign compression fracture (P = 0.866). The areas under the ROC curves of FF and FF ratio were 93% and 87%, respectively, which were higher than those of the other parameters used for differentiation (P < 0.001). In logistic regression analyses, FF remained a significant variable that could be used to independently differentiate benign from malignant lesions, with an odds ratio of 1.9 (P < 0.001).
CONCLUSION: The FF and FF ratio obtained from FF maps using modified-Dixon sequence could be used to distinguish between benign and malignant causes of focal bone marrow abnormalities when difficulty in the qualitative interpretation of conventional MR images arises. LEVEL OF EVIDENCE: 3 J. MAGN. RESON. IMAGING 2017;45:1534-1544.
© 2016 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  bone marrow malignancy; chemical shift encoded imaging; fat quantification; fat-signal fraction; modified Dixon method

Mesh:

Year:  2016        PMID: 27690264     DOI: 10.1002/jmri.25496

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  19 in total

1.  Proton density fat fraction (PDFF) MRI for differentiation of benign and malignant vertebral lesions.

Authors:  Frederic Carsten Schmeel; Julian Alexander Luetkens; Peter Johannes Wagenhäuser; Michael Meier-Schroers; Daniel Lloyd Kuetting; Andreas Feißt; Jürgen Gieseke; Leonard Christopher Schmeel; Frank Träber; Hans Heinz Schild; Guido Matthias Kukuk
Journal:  Eur Radiol       Date:  2018-01-08       Impact factor: 5.315

2.  Proton density fat fraction (PDFF) MR imaging for differentiation of acute benign and neoplastic compression fractures of the spine.

Authors:  Frederic Carsten Schmeel; Julian Alexander Luetkens; Simon Jonas Enkirch; Andreas Feißt; Christoph Hans-Jürgen Endler; Leonard Christopher Schmeel; Peter Johannes Wagenhäuser; Frank Träber; Hans Heinz Schild; Guido Matthias Kukuk
Journal:  Eur Radiol       Date:  2018-06-01       Impact factor: 5.315

Review 3.  The Dixon technique for MRI of the bone marrow.

Authors:  Niels van Vucht; Rodney Santiago; Bianca Lottmann; Ian Pressney; Dorothee Harder; Adnan Sheikh; Asif Saifuddin
Journal:  Skeletal Radiol       Date:  2019-07-15       Impact factor: 2.199

4.  Voxel-based mapping of five MR biomarkers in the wrist bone marrow.

Authors:  Louis Marage; Jeremy Lasbleiz; Maxime Fondin; Mathieu Lederlin; Giulio Gambarota; Hervé Saint-Jalmes
Journal:  MAGMA       Date:  2021-03-12       Impact factor: 2.310

5.  Advanced MR imaging of bone marrow: quantification of signal alterations on T1-weighted Dixon and T2-weighted Dixon sequences in red marrow, yellow marrow, and pathologic marrow lesions.

Authors:  Chayanit Sasiponganan; Kevin Yan; Parham Pezeshk; Yin Xi; Avneesh Chhabra
Journal:  Skeletal Radiol       Date:  2019-10-12       Impact factor: 2.199

6.  Differentiation of bone metastases from benign red marrow depositions of the spine: the role of fat-suppressed T2-weighted imaging compared to fat fraction map.

Authors:  Sekyoung Park; Jin Do Huh
Journal:  Eur Radiol       Date:  2022-07-07       Impact factor: 7.034

7.  Detection of vertebral metastases: a comparison between the modified Dixon turbo spin echo T2 weighted MRI and conventional T1 weighted MRI: a preliminary study in a tertiary centre.

Authors:  Seok Hahn; Young Han Lee; Jin-Suck Suh
Journal:  Br J Radiol       Date:  2018-03-15       Impact factor: 3.039

8.  Quantification of bone marrow edema in rheumatoid arthritis by using high-speed T2-corrected multiecho acquisition of 1H magnetic resonance spectroscopy: a feasibility study.

Authors:  Wenzhao Yuan; Yiwu Lei; Cheng Tang; Fang Qin; Jing Wen; Chenhui Li; Min Ling; Jiang Huang; Huiting Zhang; Liling Long
Journal:  Clin Rheumatol       Date:  2021-06-21       Impact factor: 2.980

9.  Fully automated radiomic screening pipeline for osteoporosis and abnormal bone density with a deep learning-based segmentation using a short lumbar mDixon sequence.

Authors:  Yinxia Zhao; Tianyun Zhao; Shenglan Chen; Xintao Zhang; Mario Serrano Sosa; Jin Liu; Xianfu Mo; Xiaojun Chen; Mingqian Huang; Shaolin Li; Xiaodong Zhang; Chuan Huang
Journal:  Quant Imaging Med Surg       Date:  2022-02

Review 10.  Quantitative MRI and spectroscopy of bone marrow.

Authors:  Dimitrios C Karampinos; Stefan Ruschke; Michael Dieckmeyer; Maximilian Diefenbach; Daniela Franz; Alexandra S Gersing; Roland Krug; Thomas Baum
Journal:  J Magn Reson Imaging       Date:  2017-06-01       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.